Perrigo (PRGO $92.90 +3.23) announced that it received final approval from the FDA for its Abbreviated New Drug Application for Guaifenesin Extended-Release Tablets.
The new product will be packaged under store and proprietary brands that will compare to Mucinex tablets. Perrigo is still in litigation with Reckitt Benckiser Group, PLC, the New Drug Application holder and patent owner of Mucinex.






